Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud

Aureon Laboratories, Inc.

Specialty Minerals (michigan) Inc.

Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud

Amcol International Corporation

Michael Donovan

Faisal Khan

Gerardo Fernandez

Peter Ajemba

Jack Zeineh

Richard Jonathan Scott

Qiuhua Liu

Janakiramanan Ramachandran

Carlos Cordon-Cardo

Marek R Mosiewicz

Ricardo Mesa-Tejada

Jose Costa

Stefan Hamann

Carlos Cardon-Cardo

Yevgen Vengrenyuk

Thomas W Beihoffer

Mark Clayton

Nataliya V Larionova

Paola Capodieci

Angeliki Kotsianti

Jason M Logsdon

Jason Alter

Dolly Batra

Nigel Webb

Christos Athanassopoulos

Valentina Bayer Zubek

Douglas Powell

Stephen Fogarasi

Ali Tabesh

Doug Powell

Douglas A Powell

Richard Scott

A method of sorbing a PFAS compound from a contaminated environment can include admixing a modified clay sorbent with the environment. The modified clay can include a clay intercalated with a blend of mono-quaternary amine compound and di-quaternary amine compound.

Modified clay sorbents and methods of sorbing PFAS using the same

This present invention systems and methods of accessing/monitoring the responsiveness of a breast cancer to a therapeutic compound.

Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer

Apparatus, methods, and computer-readable media are provided for segmentation, processing (e.g., preprocessing and/or postprocessing), and/or feature extraction from tissue images such as, for example, images of nuclei and/or cytoplasm. Tissue images processed by various embodiments described herein may be generated by Hematoxylin and Eosin (H&E) staining, immunofluorescence (IF) detection, immunohistochemistry (IHC), similar and/or related staining processes, and/or other processes. Predictive features described herein may be provided for use in, for example, one or more predictive models for treating, diagnosing, and/or predicting the occurrence (e.g., recurrence) of one or more medical conditions such as, for example, cancer or other types of disease.

Systems and methods for segmentation and processing of tissue images and feature extraction from same for treating, diagnosing, or predicting medical conditions

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.

Method and system for determining the risk of occurrence of prostate cancer

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.

System for evaluating a pathological stage of prostate cancer

A method of in situ immunohistochemical analysis of a biological sample is provided. The method allows for the multiplex and simultaneous detection of multiple antigens, including multiple nuclear antigens, in a tissue sample.

Multiplex in situ immunohistochemical analysis

The present invention relates to a method for detecting one or more nascent RNAs in a tissue sample using FISH. In the method, a plurality of probes (8 to 82) may be used to detect a single species of nascent RNA. Further, a plurality of nascent RNA species may be detected simultaneously using between 8 and 82 probes for each nascent RNA. The invention comprises, in addition, methods of preparing a sample for nascent RNA detection by reducing autofluorescence of the tissue sample. These techniques may be synergistically combined to achieve significantly improved results.

Diagnostic histopathology using multiplex gene expression FISH

Growing community of inventors

Newton, MA, United States of America

Michael Donovan